IDEXX Laboratories (IDXX)
(Delayed Data from NSDQ)
$476.27 USD
+2.99 (0.63%)
Updated Oct 11, 2024 04:00 PM ET
After-Market: $476.27 0.00 (0.00%) 7:58 PM ET
4-Sell of 5 4
D Value C Growth D Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$476.27 USD
+2.99 (0.63%)
Updated Oct 11, 2024 04:00 PM ET
After-Market: $476.27 0.00 (0.00%) 7:58 PM ET
4-Sell of 5 4
D Value C Growth D Momentum D VGM
Zacks News
Looking for a Growth Stock? Why It is Time to Focus on IDEXX Laboratories (IDXX)
by Zacks Equity Research
IDEXX Laboratories (IDXX) is seeing solid earnings estimate revision and has a favorable Zacks rank, making it well positioned for future earnings growth.
The Zacks Analyst Blog Highlights: IDEXX Laboratories, Luminex, Masimo, Align Technology and Cooper Companies
by Zacks Equity Research
The Zacks Analyst Blog Highlights: IDEXX Laboratories, Luminex, Masimo, Align Technology and Cooper Companies
5 MedTech Stocks to Beat Tax Hazards With Positive Returns
by Zacks Equity Research
Trump's tax reform policies promise to cut corporate taxes. However, the future of the U.S. MedTech industry depends on the much-awaited decision on the 2.3% medical device tax.
Medtronic (MDT) Beats on Q2 Earnings, Reiterates FY18 View
by Zacks Equity Research
Medtronic (MDT) rides high on strength in major business segments in Q2.
Patterson Companies (PDCO) Misses on Q2 Earnings, Cuts View
by Zacks Equity Research
Patterson Companies (PDCO) missed estimates for both the counts in Q2. A downbeat guidance indicates looming concerns.
Accelerate Diagnostics (AXDX) in Focus: Stock Moves 6.7% Higher
by Zacks Equity Research
Accelerate Diagnostics (AXDX) was a big mover last session, as the company saw its shares rise nearly 7% on the day.
Zacks.com highlights: Home Depot, Baxter International, IDEXX Laboratories, NVR and MAM Software Group
by Zacks Equity Research
Zacks.com highlights: Home Depot, Baxter International, IDEXX Laboratories, NVR and MAM Software Group
5 of the Most Efficient Stocks to Buy Now
by Tirthankar Chakraborty
We have considered four popular ratios in order to find efficient companies that have the potential to provide impressive returns.
DaVita Issues Downbeat '17 View, Hurricanes Affect Q3 Results
by Zacks Equity Research
Hurricanes Harvey and Irma dealt a heavy blow to DaVita's (DVA) operating income in the third quarter. Management's tepid forecast for the full year adds to the concerns.
4 Top Growth Picks to Avoid Tax Tangle in MedTech
by Zacks Equity Research
Despite the ongoing tax bill-related disputes in the MedTech industry, these stocks with high growth potential can be great bets for investors.
IDEXX Laboratories (IDXX) Q3 Earnings Beat, Revenues Miss
by Zacks Equity Research
IDEXX Laboratories (IDXX) rides high on strength in Companion Animal Group business in Q3. Moreover, a raised guidance buoys optimism.
IDEXX Laboratories (IDXX) Beats on Q3 Earnings, View Up
by Zacks Equity Research
IDEXX Laboratories (IDXX) gains on solid contributions from Companion Animal Group business in Q3.
Should You Buy IDEXX Laboratories (IDXX) Ahead of Earnings?
by Zacks Equity Research
IDEXX Laboratories (IDXX) is seeing favorable earnings estimate revision activity as of late, which is generally a precursor to an earnings beat.
PetMed (PETS) Tops Q2 Earnings & Sales Estimates, Margins Up
by Zacks Equity Research
The year-over-year rise in earnings of PetMed (PETS) was driven by an increase in sales and improved margins.
Can Companion Animal Group Drive IDEXX's (IDXX) Q3 Earnings?
by Zacks Equity Research
IDEXX Laboratories (IDXX) is poised to gain from strength in its Companion Animal Group business in Q3.
Abbott (ABT) Exceeds Q3 Earnings, '17 Guidance Narrowed
by Zacks Equity Research
Abbott (ABT) posted promising Q3 results primarily on the back of strong EPD sales and emerging market expansion.
Phibro Animal Banks on Diverse Portfolio, Competition Rife
by Zacks Equity Research
Phibro Animal (PAHC) is consistently trying to expand its product portfolio to counter the tough competition in the animal health space.
Henry Schein (HSIC) Inks Distribution Agreement with Terason
by Zacks Equity Research
Henry Schein's (HSIC) distribution agreement with Terason to distribute the latter's uSmart 3200T NexGen is likely to boost its global Medical segment business.
Here's Why You Should Buy Thermo Fisher Scientific (TMO) Now
by Zacks Equity Research
Based on a wide range of fundamental factors, Thermo Fisher (TMO) is a great pick for now.
Here's Why Investors Should Buy Integra LifeSciences Now
by Zacks Equity Research
The market is upbeat about Integra LifeSciences' (IART) latest developments that include product launches and strategic buyouts.
TransEnterix Senhance Surgical Robotic System Wins FDA Nod
by Zacks Equity Research
TransEnterix (TRXC) works on expanding in robotic surgery consistently.
Henry Schein Gains on Strategic Buyouts, Cost Concern a Woe
by Zacks Equity Research
Henry Schein (HSIC) continues to grow on dental and animal health business, thanks to merger and acquisition activity. However, rising costs continue to be a burden on the company's bottom line.
NuVasive's (NUVA) PRECICE System Gets Expanded FDA Approval
by Zacks Equity Research
NuVasive's (NUVA) latest receipt of expanded FDA 510(k) approval for PRECICE is likely to fortify its hold in the limb reconstruction and trauma market.
Here's Why Investors Should Sell Ecolab (ECL) Right Away
by Zacks Equity Research
Intensifying competition, foreign exchange volatility, higher raw material costs and integration risks are primary headwinds for Ecolab (ECL) as of now.
Abbott Banks on FDA Approvals and Buyouts, Competition Rife
by Zacks Equity Research
The market is upbeat about Abbott's (ABT) latest initiatives.